Related Experiment Videos
Lipocortin output by human endometrium in vitro
The Journal of Clinical Endocrinology and Metabolism
|July 1, 1986
Summary
Human endometrium secretes lipocortin, a phospholipase inhibitor. Dexamethasone increased lipocortin levels, while progesterone decreased them, but neither fully explained prostaglandin F2 alpha inhibition.
Area of Science:
- Reproductive biology
- Endocrinology
- Molecular pharmacology
Background:
- Lipocortin is a phospholipase A2 inhibitor.
- Steroid hormones play a role in endometrial function.
- Prostaglandin F2 alpha (PGF2 alpha) is involved in endometrial processes.
Purpose of the Study:
- To investigate the secretion of lipocortin by human endometrium.
- To determine the effects of dexamethasone and progesterone on lipocortin levels.
- To explore the relationship between lipocortin, dexamethasone, progesterone, and PGF2 alpha production.
Main Methods:
- Organ culture of human endometrium for 1-2 days.
- Radioimmunoassay (RIA) to measure lipocortin and PGF2 alpha levels.
- Treatment with dexamethasone and progesterone at concentrations of 10(-8)-10(-6) M.
Main Results:
- Lipocortin was secreted by human endometrial organ cultures.
- Dexamethasone increased lipocortin levels in the culture medium.
- Progesterone decreased lipocortin levels, but both steroids reduced PGF2 alpha output.
Conclusions:
- Lipocortin elevation does not appear to mediate progesterone's inhibition of PGF2 alpha production.
- Dexamethasone may inhibit PGF2 alpha via lipocortin-dependent and independent pathways.
- Steroid modulation of endometrial PGF2 alpha involves complex mechanisms beyond simple lipocortin induction.